Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Publication ,  Journal Article
Muir, AJ; Gong, L; Johnson, SG; Lee, MTM; Williams, MS; Klein, TE; Caudle, KE; Nelson, DR ...
Published in: Clin Pharmacol Ther
February 2014

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2014

Volume

95

Issue

2

Start / End Page

141 / 146

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Pharmacology & Pharmacy
  • Interleukins
  • Interferons
  • Interferon-alpha
  • Interferon alpha-2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Gong, L., Johnson, S. G., Lee, M. T. M., Williams, M. S., Klein, T. E., … Clinical Pharmacogenetics Implementation Consortium (CPIC), . (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther, 95(2), 141–146. https://doi.org/10.1038/clpt.2013.203
Muir, A. J., L. Gong, S. G. Johnson, M. T. M. Lee, M. S. Williams, T. E. Klein, K. E. Caudle, D. R. Nelson, and D. R. Clinical Pharmacogenetics Implementation Consortium (CPIC). “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Clin Pharmacol Ther 95, no. 2 (February 2014): 141–46. https://doi.org/10.1038/clpt.2013.203.
Muir AJ, Gong L, Johnson SG, Lee MTM, Williams MS, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141–6.
Muir, A. J., et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Clin Pharmacol Ther, vol. 95, no. 2, Feb. 2014, pp. 141–46. Pubmed, doi:10.1038/clpt.2013.203.
Muir AJ, Gong L, Johnson SG, Lee MTM, Williams MS, Klein TE, Caudle KE, Nelson DR, Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141–146.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2014

Volume

95

Issue

2

Start / End Page

141 / 146

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Pharmacology & Pharmacy
  • Interleukins
  • Interferons
  • Interferon-alpha
  • Interferon alpha-2